APA (7th ed.) Citation

Barbanti, P., Egeo, G., Aurilia, C., d’Onofrio, F., Albanese, M., Cetta, I., . . . Group, f. t. F. (2022, April). Fremanezumab in the prevention of high-frequency episodic and chronic migraine: A 12-week, multicenter, real-life, cohort study (the FRIEND study). The Journal of Headache and Pain.

Chicago Style (17th ed.) Citation

Barbanti, Piero, et al. "Fremanezumab in the Prevention of High-frequency Episodic and Chronic Migraine: A 12-week, Multicenter, Real-life, Cohort Study (the FRIEND Study)." The Journal of Headache and Pain Apr. 2022.

MLA (9th ed.) Citation

Barbanti, Piero, et al. "Fremanezumab in the Prevention of High-frequency Episodic and Chronic Migraine: A 12-week, Multicenter, Real-life, Cohort Study (the FRIEND Study)." The Journal of Headache and Pain, Apr. 2022.